MiddleBrook Pharmaceuticals, Inc. (MBRK)
Q1 2009 Earnings Call Transcript
May 7, 2009 9:00 am ET
Executives
Faith Pomeroy-Ward – Executive Director, IR & Corporate Communications
John Thievon – President and CEO
Dave Becker – EVP and CFO
Analysts
Richard Silver – Barclays Capital
Presentation
Operator
Good morning, my name is Jackie and I will be your conference operator today. At this time, I would like to welcome everyone to the MiddleBrook 2009 first quarter results conference call. All lines have been placed on mute to prevent any background noise. (Operator instructions). Thank you. Ms. Pomeroy-Ward, you may begin your conference
Faith Pomeroy-Ward
Thank you, Jackie and good morning everyone. Before we begin our call, I would like to remind you that some of the statements made during this call may be considered forward-looking statements. The company’s SEC filings including the 8-K filed this morning identify certain factors that could cause the company’s actual results to differ materially from those projected in any forward-looking statements made today. The company’s SEC filings as well as our press release detailing the financial and operational results discussed on today's call are available on our website at middlebrookpharma.com.
I am joined on today's call by President and CEO, John Thievon, and our Executive Vice President and CFO, Dave Becker. We expect today's call to last no more than 30 minutes including Q&A.
Now, I will turn the call over to John.
John Thievon
Thank you, Faith and good morning everyone. Welcome to our call. The first quarter of 2009 was a productive one for MiddleBrook as we launched MOXATAG to trade and prepare for it's professional launch. We launched MOXATAG to healthcare professionals nationwide on March 16, 2009, while it is still very early in the launch there, indicators that we were making very good progress.
First I will run through some of the numbers and then I will share some of our findings in the field. For the first quarter of 2009, we produced revenue of $9 million, 7.5 million of which was from MOXATAG. As you can see from the net sales for MOXATAG we received solid support from our trade customers. Approximately 20,000 retail pharmacies participated in our order ship program to place a bottle of MOXATAG on the shelf in those pharmacies prior to professional promotion. This does not include pharmacies ordering independently of order ship programs.
And now that we have 300 sales reps and manager detailing healthcare professionals nationwide and driving prescriptions to pharmacies we expect distribution to increase. Keep in mind in accordance to IMS health about 40% of the annual prescription for strep throat are filled April through September. So, it’s a great time for our field force to be building awareness among healthcare professionals across the country and working to generate prescriptions for MOXATAG.
No comments:
Post a Comment